Indole aminoketones

ABSTRACT

THEIR SALTS AND QUATERNARY AMMONIUM COMPOUNDS, AS WELL AS THEIR OPTICALLY ACTIVE ISOMERS OR DIASTEREOMERS WHEREIN R1 to R4 represent hydrogen, halogen, lower alkyl, aralkyl, phenyl, hydroxyl, lower alkoxy, nitro or lower carboalkoxy, R5 and R6 are hydrogen or methyl, R7 and R8 are hydrogen, halogen or lower alkoxy, X is a heterocyclic ring system, mono- or condensed bicyclic, with 1 - 4 hetero atoms, in which the individual rings have 5 to 6 members and can also contain 1 or more carbonyl groups, Y is -CO-or -CH(OH)-. These compounds have pharmacological activity in that they increase the coronary blood flow by simultaneously causing dilation of the coronaries and an increase in contraction strength.   Compounds of the formula

United States Patent 1191 Posselt et al.

11] 3,859,305 1451 Jan. 7, 1975 22 Filedr Apr. 26, 1971 211 App]. No: 137,575

Related U.S. Application Data [60] Continuation-in-part of Ser. No. l8,300, March 10, 1970, Pat. No. 3,658,845, Division of Ser. No. 693,l38, Dec. 26, 1967, Pat. NO. 3,514,465.

[52] U.S. Cl.. 260/326.15, 260/288 A, 260/295 R, 260/296 R, 260/302 R, 260/306.7, 260/310 R, 260/326.l5, 260/326.3, 424/274 [51} Int. Cl C07d 27/56 [58] Field of Search 260/326.14 R, 326.15

[56] References Cited UNITED STATES PATENTS 3,371,098 2/1968 Kralt et al. 260/326.l4 R

Primary Examiner-Joseph A. Narcavage Attorney, Agent, or Firm-Cushman, Darby & Cushman [57] ABSTRACT Compounds of the formula R l 2 l cn(on)' 7 RT a their salts and quaternary ammonium compounds, as well as their optically active isomers or diastereomers wherein R to R represent hydrogen, halogen, lower alkyl, aralkyl, phenyl, hydroxyl, lower alkoxy, nitro or lower carboalkoxy, R and R are hydrogen or methyl, R and R are hydrogen, halogen or lower alkoxy, X is a heterocyclic ring system, mono or condensed bicyclic, with 1 4 hetero atoms, in which the individual rings have 5 to 6 members and can also contain 1 or more carbonyl groups, Y is COor '-CH(Ol-l). These compounds have pharmacological activity in that they increase the coronary blood flow by simultaneously causing dilation of the coronaries and an increase in contraction strength.

14 Claims, N0 Drawings INDOLE AMINOKETONES a. reacting a compound of the formula 3/ )t CO C11 11 R R with a compound of the formula 11] H N C|21l(011) R in the presence of formaldehyde or a formaldehyde source and a solvent.

b. Reacting a compound of the formula x-co-c='cn 1 3/, I 2

or the corresponding Mannich base of the formula 1 2 R 9 R l R X--.CO--CH--CH --N v wherein R and R are lower alkyl with a compound of formula III or c. reacting a compound of the formula it. t a

2 with a compound of the formula R v CH 011(011) 8 vn A R in which W and V are different and are either halogen or Nl-l in the presence of a basic substance and, if desired, in the event Y is CO, reducing such group to a CH(OH) group and, if desired, converting the bases produced into their pharmacologically acceptable acid addition salts or quaternary ammonium salts.

The process according to method a) is carried out in the usual manner at a temperature between and NH CH CH (OH) I 5 like come into consideration as solvents.

The process according to method b) in general when using an unsaturated ketone of formula N can be carried out at temperatures between 20 and C in an inert solvent, such as, ether, acetone, dioxane or chloroform, whereas when the corresponding Mannich base is used, which during the reaction is transformed into an intermediate of formula IV, the reaction temperature used is normally higher, preferably, between 80 and C, and solvents such as water, alcohol/water, or a two phase system such as benzene/water toluene/water come into consideration.

The process according to method c) is usually carried out at elevated temperatures in a solvent such as alcohols, ether, dimethyl formamide and the like.

The compounds produced which contain optically active carbon atoms and which as a rule are produced as racemates can be resolved into their optically active isomers in the usual manner, for example, with the aid of an optically active acid. It, however, is also possible to employ optically active compounds or diastereomers as the starting materials whereby the end product in the corresponding pure optically active form or diastereomeric configuration is obtained.

The free bases can be converted into their salts with the usual pharmacologically acceptable acids such as HCl, HBr, H SO acetic acid, citric acid, succinic acid, maleic acid, fumaric acid, lactic acid, p-toluene sulfonic acid and the like. Those compounds containing basic tertiary nitrogen atoms can be converted to their quaternary salts with the usual phar'macologically acceptable quaternizing agents such as the lower alkyl halides. The free bases can be removed from the salts, for example, by treatment with aqueous NaOH and other salts can be prepared from such free bases.

As already indicated, the compounds according to the invention have a pharmacological activity in that they increase the coronary blood flow by causing dilation of the coronaries, as well as an increase in contraction strength of the heart.

When tested on the isolated guinea pig heart according to Langendorff (Pflugers Arch. 61, 291, 1895) it was found that the compounds according to the invention were active in doses between 10 500 ug/heart (pig e microgram) in dilating the coronaries while simultaneously increasing the contraction strength.

The indications for the compounds according to the invention are:

- Coronary insufficiency Angina pectoris Myocardial infarct Myocardial insufficiency Circulatory disturbances of various geneses Disturbances of the peripheral and cerebral blood flow Migraines Artcriosclerosis The novel compounds can be used, if desired, also in combination with other medicaments in the form of pharmaceutical compositions suited for enteral, parenteral, oral or per lingual application.

The acute toxicity of the compounds according to the invention when tested on mice by the-method of Miller and Tainter (Proc. Soc. exper. Biol. a Med 57, 261, 1944) expressed as the LD 50 is between 100 mg/kg and 5000 mg/kg oral.

The individual doses for human beings, depending on form of administration are between 0,5 and 100 mg, once or more times a day.

The following examples will serve to illustrate the compounds according to the invention. For sake of simplicity the symbol Z is used in the structural formulae and nomenclature of a number of the examples to represent, respectively -cu -cii -IH-cl:tt CH(O 1) Q f on and 2-[3-phenyl-3-hydroxy-propyl-(2)-amino]-ethyl EXAMPLEl 1- 2-[3-phenyl-3-,hydroxy-propyl-(2)-amino]-ethyl thienyl-(2)-ketone, that is, 1- Z -thienyl-(2)-ketone Method a.

12.6 g (0.1 mol) of 2 acetylthiophene, 18.7- g (0.1 mol) of l-norephedrine O HCl and 4 g (0.13 mol) of paraformaldehyde were dissolved in 20 ml of isopropanol and after addition of 0.2 mol of concentrated HCl boiled under reflux for 2 hours. Thereafter 100 ml of acetone were added to the still warm solution. The hydrochloride which crystallized out upon cooling was purified by recrystallization from ethanol. lts melting point was 191 192 C and the yield 17 g.

Method b-.

1.5 g (0.01 mol of l-norephedrine were dissolved in 50 ml of ether and 2.7 g (0.02 mol) of thienyl vinyl ketone dissolved in ml of ether added thereto. After 12 hour 2 g ofthe base separated out which after recrystallization from ethanol had a melting point of 1 18 120 C. The hydrochloride produced therefrom had a melting point of 191 192 C. Method c.

5.2 g (0.03 mol) of Z-[B-chloropropionyl]-thiophene were dissolved in dimethyl formamide and united with a solution of 4.5 g (0.03 mol) of l-norephedrine and 4 g (0.03 mol) of triethylamine in 25ml of dimethyl formamide. After 1 hour the triethylamine HCl which was formed was filtered off and the filtrate acidified with isopropanolic HCl. Subsequently, the HCl salt was precipitated from the solution by addition of ether and recrystallized from ethanol. lts melting point was 191 192 C and the yield was 7'g.

EXAMPLE 2 l- Z -phenyl-(2)-ketone EXAMPLE 3 l- Z -[4-methyl-thiazolyl-(2)]-ketone 7 g (0.05 mol) of 4-methyl-Z-acetyI-thiazole, 9.4 g (0.05 mol) of l-norephedrine HCl, 2 g (0.067 mol) of paraformaldehyde and 5 drops of isopropanolic HCl in 20 ml of isopropanol were reacted and processed as in Example 2. The HCl salt was recrystallized from methanol. Its melting point was 197 199 C and the yield 7 g.

EXAMPLE 4 '1- Z -antipyryl-(4)-ketone N CH c 0 CH3 (12C- 11.5 g of 4 -acetyl-antipyrin (0.05 mol), 9.5 g of 1- norephedrine l-lCl (0.05 mol) and 2 g of paraformaldehyde (0.067 mol) were introduced into 20 ml of isopropanol and 5 drops of isopropanolic l-lCl added thereto and the mixture boiled for a total of 5 hours during which after 3 hours an additional 1 g of paraformaldehyde was added. Thereafter the solvent was distilled off and'the residue treated with aqueous soda. The oily Mannich base produced was crystallized with the aid of ether. It formed the dihydrochloride with 2 mol of HCl which was recrystallized from ethanol. lts

melting point was 206 208 C and the yield was 9 g.

' EXAMPLE 5 I 1- Z -pyridyl-(3)-ketone 40 g (0.33 mol) of 3-acetyl-pyridine, 18.7 g (0.1 mol) of l-norephedrine HCl and 3 g (0.1 mol) of paraformaldehyde were boiled under reflux in ml of isopropanol for a total of 3 hours. An additional 1 g of paraformaldehyde was added after 1 hour. Thereafter the reaction mixture was diluted with acetone and the precipitated HCl salt was recrystallized from methanol/ethanol (1:2). lts'melting point was 187 189 C and the yield 7 g. I

EXAMPLE 6 1 Z -[2,4-dimethyl-thiazolyl-(5)]-ketone en 3 CH C02 3 S 25 g (0.16 mol) of 2,4-dimethyl-5-acetyl-thiazole, 30 g (0.16 mol) of l-norephedrine HCl and 5 g (0.16 mol) of paraformaldehyde were introduced into 50 ml of isopropanol and 15 drops of isopropanolic HCl added thereto. The mixture was boiled on a water bath for a total of 1 hour. An additional 1.5 g of paraformaldehyde was added after 76 hour. The reaction solution was diluted with 100 ml of acetone while still warm. The HCl salt which precipitated out was recrystallized from 80% ethanol. lts melting point was 208 210 C and the yield 6.6 g.

EXAMPLE 7 1- Z -[4-methyl-Lhydroxy-thiazolyl-(5)]-ketone N CH 3 HO 4 C02 5 g (0.035 mol) of 4-meth'yl-2-hydroxy-5- acetylthiazole, 6.6 g (0.035 mol) of l-norephedrine HCl and 1.5 g (0.05 mol) of paraformaldehyde were 'boiled under reflux for 2 hours in ml of glacial acetic acid. The HCl salt which crystallized out on cooling was recrystallized from methanol/ethanol (1:1). Its melting point was 209 210 C and the yield 4.5 g.

EXAMPLE 8 l- Z -cumaronyl-ketone 40 g (0.25 mol) of 2-acetyl cumarone, 46.5 g (0.25 mol) of l-norephedrine HCl and 7.5 g (0.25 mol) of paraformaldehyde were dissolved in 200 ml of isoamyl alcohol and after addition of 10 drops of ethanolic HCl boiled under reflux for '16 hour. Then an additional 2.5 g (0.083 mol) of paraformaldehyde were added and the mixture refluxed for a further V4 hour. The solution was diluted with 100 ml of acetone while still warm. Upon cooling the HCl salt crystallized out. It was recrystallized trom ethanol. lts melting point was 199- 200 C and the yield 31.5 g.

EXAMPLE 9* 1-3- 3-[ 3-phenyl-3-hydroxy-propyl-(2 )-anlino]-propionyl -thionaphthene EXAMPLE 10 1-3- 3 phenyl-3-hydroxy-propyl-(2)-amino]- propionyl -1-methyl-indole I I coz 1-:: I

25 g (0.13 mol) of l-methyl-3-acetyl-indole, 24.3 g.

(0.13 mol)'of l-norephedrine HCl and 5 g (0.17 mol) of paraformaldehyde were dissolved in m1 of isopropanol and boiled under reflux for a total of 6 hours. After the second and fourth hours an additional 2.5 g of'paraformaldehyde were added. Thereafter the solvent was distilled off and the residue dissolved in warm acetone. The HCl salt which crystallized out on cooling was recrystallized from ethanol. lts'melting point was 194 195 C and the yield 22 g.

EXAMPLE 1 1 1'5-[ 3-[ 3-phenyl-3-hydroxy-propyl-( 2 )-amino]- propionyl]-benzodioxol-( 1,3)

8 g (0.048 mol) of 5-acetyl-benzodioxol-(1,3), 91.1 g (0.048 mol) of l-norephedrine HCl and 2.9 g (0.097 mol) of paraformaldehyde were boiled on a water bath for 2 hours in 30 ml of isopropanol after addition of 5 drops of isopropanolic HCl. After addition of 100 m1 of acetone to the warm reaction solution, the HCl salt precipitated out. It was recrystallized from ethanol. lts melting point was 195 197 C and the yield 9 g.

EXAMPLE 12 l-4- 3-[ 3-phenyl-3-hydroxy-propyl-( 2 )-amino]- propionyl -l ,3-dimethyl and -l,5-dimethyl pyrazole (mixture) an I CO Z 26 g (0.19 mol) of the isomeric mixture of 1,3-and 1,5-dimethyl-4-acetyl-pyrazole formed during the synthesis, 37.4 g (0.2 mol) of l-norephedrine HCl and 9 g (0.3 mol) of paraformaldehyde were boiled under reflux under an atmosphere of nitrogen in 150 ml of isopropanol for 3 hours. Upon cooling the HCl salt crystallized. It was recrystallized from isopropanol and then twice. from ethanol. lts melting point was 196 C and the yield 11 g.

EXAMPLE 13 1- Z -quinolyl-(3)-ketone l Ti I 10 g (0.058 mol) of 3-acetyl quinoline, 11.2 g (0.058 mol) of l-norephedrine HCl and 1.6 g (0.058 mol) of paraformaldehyde were boiled under reflux on a water bath in 75 ml of isopropanol for 2.5 hours. An additional 0.8 g (0.026 mol) of paraformaldehyde was added after 1 hours boiling. Upon addition of 150 ml of acetone the HCl salt precipitated out. It was recrystallized from 80% methanol. Its melting point was 205 206 C and the yield 5 g.

EXAMPLE 14 g 1- Z -isoquinolyl-(4)-ketone CW \/\/N 5 g (0.024 mol) of 4-acetyl isoquinoline HCl, 4.6 g

(0.024 mol) of l-norephedrine HCl and 0.7 g (0.024 mol) of paraformaldehyde were boiled on a water bath for 2.5 hours in 50 ml of a 1:1 mixture of ethanolisopropanol and an additional 0'.4 g (0.012 mol) of paraformaldehyde was added after 1 hours boiling. Upon cooling, the dihydrochloride salt precipitated out. It was recrystallized from ethanol. lts melting point was 208 C and the yield 3 g.

EXAMPLE 15- 1- Z -[1,2,4-trimethyl-5-carbethoxypyrrolyl-(3)]- ketone c 11 ooc 18 g (0.081 mol) of 1,2,4-trimethyl-3-acetyl-5-carbethoxypyrrole, 15.2 g (0.081 mol) of 1-norephedrine HCl and 2.4 g (0.081 mol) of paraformaldehyde were boiled on a water bath for 1.5 hours in 50 ml of isopropanol. An additional 1.2 g of paraformaldehydewere added after 1% hours boiling. Upon addition of 100 ml of acetone the HCl salt precipitated out. it was recrystallized from ethanol. lts melting point was 178 180 C and the yield 10 g.

EXAMPLE 16 1-6 3-[3-phenyl-3-hydroxy-propyl-(2)-amino]- propionyl -benzodioxane-( 1,4)

11.7 g (0.066 mol) of 6-acetyl-l,4-benzodioxane, 12.5 g (0.066mol) of l-norephedrine HCl and 2 g (0.067 mol) of paraformaldehyde were boiled on a water bath in 33 ml of isopropanol for 2 hours. An additional 2 g (0.067 mol) of paraformaldehyde were added after 1 hours boiling. The solvent was distilled off and the residue treated with acetone. The HCl salt which precipitated out was recrystallized from ethanol. lts melting point was 201 C and the yield 7.5 g.

EXAMPLE 17 I 1-2- 3-[3-pheny1-3-hydroxy-propyl-(2)-amino]- propionyl -benzodioxane-( 1,4)

11 g (0.061 mol) of 2-acety1-1,4 benzodioxane 11.6

v g (0.062 mol) of l-norephedrine HCl and 1.85 g

(0.062 mol) of paraformaldehyde were reacted in 30 ml of isopropanol and processed as in Example 16. The melting point of the HCl salt was 178 C and the yield 8 g.

EXAMPLE 18 I- Z -[2-benzy1-10-hydroiry-decahydroisoquinolyl- (4 ]-ketone EXAMPLE 19 1- Z -[5-nitro-furyl-(2)]-ketone i n co 2" 3 o 11.6 g (0.075 mol) of 2-acetyl-5-nitro-furane, 14 g (0.075 mol) of l-norephedrine HCl and 3 g (0.1 mol) of paraformaldhyde in 50 ml of isopropanol were heated on a water bath for 3 hours. The HCl salt which precipitated out upon cooling was recrystallized from 9 80% ethanol. Its melting point was 210 C and the yield 3 g.

EXAMPLE 20 1-4- 3-[3-phenyl-3-hydroxy-propyl-(2)-amino]- propionyl -1,3,5-trimethyl pyrazole CH CO Z l CH 27 g (0.178 mol) of l,3,5-trimethyl-4-acetylpyrazole, 33 g (0.177 mol) of l-norephedrine HCl and 10.8 g (0.36 mol) of paraformaldehyde in 150 ml of isopropanol were heated for 2 hours on a water bath. Thereafterthe solvent was distilled off and 100 ml acetone were added to the residue. The HCl salt which precipitated was recrystallized from isopropanol. Its melting point was 191 C and the yield was 14.5 g.

EXAMPLE 21 1-4- 3-[3-phenyl-3-hydroxy-propyl-(2)-amino]- propionyl -1-benzyl-3,S-dimethyl-pyrazole CH Z 3 h J I N CE! \N 3 13.5 g (0.0624 mol) of 3,5-dimethyl-l-benzyl-4- acetyl-pyrazole, 11.1 g (0.0593 mol) of l-norephedrine HCl and 3.6 g (0.12 mol) of paraformaldehyde were heated on a water bath in 200 ml of isopropanol for 2 hours. The HCl salt precipitated out from the reaction solution after addition of 100 ml of acetone and it was recrystallized from ethanol. Its melting point was 200 C and the yield 11 g.

EXAMPLE 22 d,1- 2-[3-(3-fluoro-4-methoxy-phenyl)-3- hydroxypropyl-(2)-amino]-ethyl -thienyl-(2)-ketone l lS -co-cu -c11 l 7 NH CH -.CH(OH) CCH3 28 g (0.119 mol) of d,1-3-(3-fluoro-4- methoxyphenyl)-3-hydroxy-propyl-(2)-amine 1-1C1,' 15 g (0.119 mol) of Z-acetyl-thiophene and 7.2 g (0.24 mol) of paraformaldehyde were reacted in 200 ml of isopropanol and processed as in Example 21. The HCI salt was recrystallized from ethanol. Its melting point was 208 C and the yield was 10 g.

EXAMPLE 23 l- 1-[3-phenyl-3-hydroxy-propyl-(2)-amino]-propyl- (2) -thienyl-(2)-ketone CII 1 3 CO CH C11 111-1 1 cu c1-r(oi-r)' 43 g (0.307 mol) of 2-propionyl-thiophene, 57.7 g (0.308 mol) of l-norephedrine HCl and 18.4 g (0.614 mol) of paraformaldehyde were heated on a water bath in 50 ml of isopropanol for 1 hour. ml of acetone were added to the reactionsolution and the HCl salt which precipitated out recrystallized from ethanol. Its melting point was 208 C and the yield was 16.5 g.

EXAMPLE 24 1- Z -5-chloro-thienyl-(2) -ketone 30 g (0.187 mol) of 2-acetyl-5-chloro-thiophene, 35 g (0.187 mol) of l-norephedrine HCl and 5.6 g (0.187 mol) of paraformaldehyde were heated in 50 ml of isopropanol and processed as in Example 21. The I-IC] salt was recrystallized from ethanol. Its melting point was 198 C and the yield was 16 g. 8

EXAMPLE 25 d,1- 2-[2-(2-chloro-phenyl)-2-hydroxy-ethylamino]- ethyl -thienyl-(2)-ketone S l -ICO'- CH Cll EXAMPLE 26 [3-phenyl-3-hydroxy-propyl-(2)]- 3-[4 phenylthiazolyl-(2)]-3-hydroxy-propyl-(l -amine CH( OH) Z 6 g (0.015 mol) of 1- Z -[4-phenyl-thiazolyl-(2)]- ketone HCl were suspended in 60 ml of methanol and reduced by the addition of 0.6 g (0.016 mol) of sodium borohydride. After 1 hour the solvent was distilled off and the residue dissolved in acetone. Fumaric acid was added to such solution to precipitate out the fumarate salt. The base was again set free from the fumarate with aqueous NaOI-I. The resulting oily base was taken up in ether and converted to the HCl salt with isopropanolic I-lCl and such salt recrystallized from ethanol. Its melting point was 178 181 C and the yield was 2.5 g.

11 EXAMPLE 27 [3-phenyl-3-hydroxy-propyl-(2)]- 3-[thienyl-(2)]-3- hydroxy-propyl-( 1) -amine 63 g (0.2 mol)'of l- Z -thien-yl-(2)-ketone. HCl and 300 g of aluminum isopropylate were heated to 130 C for 2 hours in 2 liters of isopropanol and the acetone produced during the reduction distilled off over a column. After 7 hours the cooled solution was decomposed by addition of 100 g of citric acid in 200 ml of water and then rendered strongly alkaline with aqueous NaOH. The organic phase was dried over calcium oxide and the solvent distilled off under vacuum. The amino alcohol product melted at 123 125 C after it was recrystallized from 50% ethanol. Upon addition of an equimolar quantity of HCl a HCl salt was obtained which had a melting point of 152 155 C. The yield was 13 g.

EXAMPLE 2s [3-phenyl-3 -hydroxy-propyl-(2 3-[cumaronyl-( 2 3-hydroxy-propyl-( 1) -amine l l CH(011) 2 o centrated HCl were added and the NaCl produced filtered' off. The solvent was then distilled off under vacuum and the residue recrystallized from isopropanol- /ethyl acetate (1:1). The HCl salt produced melted at 210 215 C with decomposition. The yield was 11 g.

EXAMPLE 29 came) z 19 g (0.05 mol) 1-3-]phenyl-3-hydroxy-propyl-(2)- amino]-propionyl -thionaphthene HCl were suspended in 100 ml of ethanol and reduced with 2 g of sodium borohydride in 50 ml of ethanol at room temperature. After 1 hour the reaction'mixture was filtered and the solvent distilled off and the residue dissolved in ether. The HCl salt was precipitated from the ether solution by addition of ethanolic HCl and recrystallized from isopropanol. Its melting point was 167 170 C and the yield was 12 g.

The indole compounds of the present invention in addition to the pharmacological activities noted earlier have an inflammation repressing activity. Their antiphlogistic activity is much stronger than their heart circulatory activity.

The antiphlogistic action of the indoles were tested on the carrageenin edema of the rats paw using the method of Domenjoz et al (Arch. exp. PharmQPath 230 (1957) 325).

In these tests, when the compounds were applied orally at dosages in the range of 1 to 500 mg/kg of body weight strong antiphlogistic activity was noted. The best of the compounds had an edema repression of 50% at an oral dosage of 5 to 20 mg/kg.

To estimate the activity, the known antiphlogistic compound salicylamide was used as a standard. Lower dosages were required with most of the compounds of the invention to get an activity equal to that of salicylamide.

The indications for the compounds of the invention as inflammation repressing medicines are chronic polyarthritis rheumatic illnesses post traumatic inflammations swellings at fractures thrombophlebitis in any form (including post operative) bursitis synovitis collagenoses (polymyositis, periartiitis) gout The pharmacological handling of the compounds is according to the customary standard procedures, if desired in combination with other pharmaceutically active materials. The application, for example, can be enteral, parenteral, oral or per lingual as set forth above. The individual dose according to the indicated field and type of dispensing can be between 0.1 and 500 mg., one or more. times a day.

Additional Examples of suitable indole compounds are set forth below EXAMPLE 30 l-3- 3-[3-phenyl 3-hydroxypropyl-(2)-amino]- propionyl indole pmom w C0-CH2-CH2-N11-(1H I n on EXAMPLE 31 l-3 3-[3-phenyl3-hydroxypropyl-(2)-amino]-propionyl -l,2-dimethyl indole 24 grams (0.128 mole) of 1,2-dimethyl-3-acetyl indole, 20 grams (0.132 mole) of l-norephedrine and 4 grams of paraformaldehyde (equivalent to 0.133 mole of formaldehyde) were dissolved in 70 ml. of isopropanol, adjusted to a pH of 3 with isopropanolic HCl and The salts, e.g. the hydrochloride salts within the present invention are useful as curing agents for melamineformaldehyde resins.

What is claimed is:

1. A compound having the formula:

heated at reflux for 6 hours. The HCl salt of the title compound of the example was precipitated from the reaction solution with ether and recrystallized from methanol, M.P. 190192C. yield 13 grams.

EXAMPLE 32 l-3- 3-[3-phenyl-3-hydroxypropyl-(2)-amino]- propionyl -2-methyl-5 methoxy indole .1 i ch 0 co-ctl ca naln N 7 CH 9.5 grams (46.7 millimoles) of 2-methyl-5-methoxy- 3-acetyl indole, 9.5 grams (50.7 millimoles) of lnorephedrin.HCl and 1.5 grams of paraformaldehyde (equivalent to 50 millimoles of formaldehyde) were heated at reflux for hours in a mixture of 40 ml. of isopropanol and 10 m1. of dimethyl formamide, wherein after 3 hours 0.7 grams of paraformaldehyde was added. The solvent was distilled off and the residue dissolved in acetone. The HCl salt of the title compound of the example gradually crystallized out and was recrystallized from a mixture of methanol and ether (-lto 1 parts by volume). M.P. 213C. yield 4.5 grams.

ln addition to the indole compounds set forth above other indole compounds within the invention include l-2- 3-[3-phenyl-3-hydroxy-propyl-(2)-amino]-propionyl -l-methyl indole; l-3- 3-[3-phenyl-3- hydroxypropyl-(2)-amino]-propionyl -1-methyl-2- hydroxy indole; l3- 3-[3-phenyl-3-hydroxypropyl-(2)- aminol-propionyl '1-met'nyl-2-methoxy indole; 3- 3- [phenyl-3 hydroxyethyl-(2)-amino]-propionyl -1- ethyl indole; 3- 3-[3-phenyl-3-hydroxypropyl-(2)- amino]propionyl 1,2,4-trimethyl indole; 3- 3-[3- phenyl-3-hydroxypropyl-(2)-amino]-propionyl -2- cabethoxy indole; 3- 3-[3-phenyl-3-hydroxypropyl- (2)-amino]-propionyl -l-methyl-5-chloroindole; 3- 3 [3-phenyl-3-hydroxypropyl-(2)-amino]-propionyl -lmethyl-2-phenyl indole; [3-phenyl-3-hydroxypropyl- (2)]- 3-[l-phenyl indolyl-(2)]-3-hydroxypropyl-(1) amine.

their pharmacologically acceptable salts and their pharmacologically acceptable quaternary ammonium salts where R is H or methyl, ethyl R is selected from the group consisting of hydrogen, methyl, phenyl, hydroxyl, and carbethoxy, R is selected from the group consisting of hydrogen, halogen, methoxy, R and R are hydrogen or methyl, R and R are hydrogen, and and Y is selected from the group consisting of CO- and CH(OH).

2. A compound according to claim 1 wherein R is hydrogen and Y is in the 3 position.

3. A compound according to claim 2 wherein R is hydrogen, R is methyl and Y is CO.

4. A compound according to claim 3 wherein R is hydrogen methyl.

5. A compound according to claim 1 wherein R is H or methyl, R is H or methyl, and R is H or methoxy.

6. A compound according to claim 5 which is l-3[3- [3-phenyl-3-hydroxypropyl-(2)-amino]-propionyl]-lmethyl indole. I

7. A compound according to claim 4 which is l-3- 3 [3-phenyl-3-hydroxypropy1-(2)-amino]-propionyl indole.

8. A compound according to claim 4 which is l-3- 3- [3-phenyl-3-hydroxypropyl-(2)-amino]-propionyl 1,2-dimethyl indole.

9. A compound according to claim 1 wherein R is methoxy and Y is in the 3 position.

10. A compound according to claim 9 which is l-3- 3 [3-phenyl-3-hydroxypropyl-(2)-amino]-propionyl Z-methyl-S-methoxy indole 11. A compound according to claim 1 wherein Y is in the 3 position.

12. A compound according to claim 1 wherein Y is in the 2 position.

13. A compound according to claim 12 wherein R is methyl.

UNITED STATES PATENT OFFICE CERTIFICATE OF CQRRECTION Patent: No. 3,359,305 pared January 7, 1975 Inv n Klaus Egsselt and Kurt Th-iele It: is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

On the cover page after the line beginning [21] insert [30] foreign application priority. date December 30, 1966 Germany B51910 and B51911.

Signed and sealed this 3th day of April L375.

(SEAL) Attest C. MARSHALL DAN-N RUTH I=ASON Commissioner of Patents Attesting 0fficer and Trademarks FORM PO'WSO u'scoMM-oc mule-rm;

. ll GOHIIMKNI PIINII-U n'llll "l, U "I ll 

1. A COMPOUND HAVING THE FORMULA:
 2. A compound according to claim 1 wherein R9 is hydrogen and Y is in the 3 position.
 3. A compound according to claim 2 wherein R5 is hydrogen, R6 is methyl and Y is -CO-.
 4. A compound according to claim 3 wherein R4 is hydrogen methyl.
 5. A compound according to claim 1 wherein R3 is H or methyl, R4 is H or methyl, and R9 is H or methoxy.
 6. A compound according to claim 5 which is l-3(3-(3-phenyl-3-hydroxypropyl-(2)-amino)-propionyl)-1-methyl indole.
 7. A compound according to claim 4 which is l-3-(3-(3-phenyl-3-hydroxypropyl-(2)-amino)-propionyl)-indole.
 8. A compound according to claim 4 which is l-3-(3-(3-phenyl-3-hydroxypropyl-(2)-amino)-propionyl)-1,2-dimethyl indole.
 9. A compound according to claim 1 wherein R9 is methoxy and Y is in the 3 position.
 10. A compound according to claim 9 which is l-3-(3-(3-phenyl-3-hydroxypropyl-(2)-amino)-propionyl)-2-methyl-5-methoxy indole
 11. A compound accordinG to claim 1 wherein Y is in the 3 position.
 12. A compound according to claim 1 wherein Y is in the 2 position.
 13. A compound according to claim 12 wherein R4 is methyl.
 14. A compound according to claim 13 wherein Y is -CO-. 